Business Context and Reporting Period
This Form 6-K is filed by FSD Pharma Inc. (not Quantum Biopharma Ltd.) for the month of September 2021, with a filing date of September 24, 2021. The registrant is a foreign private issuer headquartered in Toronto, Ontario, Canada. The filing primarily serves to incorporate by reference a Material Change Report dated September 21, 2021.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to disclose a material corporate event rather than a financial results report.
Material Changes
- Acquisition Completion: The company completed the acquisition of 100% of the issued and outstanding shares of Lucid Psycheceuticals Inc. on or before September 21, 2021.
- Regulatory Reference: Details regarding this acquisition are contained in the Material Change Report (Exhibit 99.1) incorporated by reference into the registrant's Registration Statements on Form F-10.
Guidance, Outlook, and Risks
The filing text does not contain specific management commentary, financial guidance, outlook, or a discussion of risks and contingencies beyond the disclosure of the acquisition event. Investors are directed to the incorporated Material Change Report for further details.
Investor Verification Checklist
- Verify the terms and consideration paid for the acquisition of Lucid Psycheceuticals Inc. in the Material Change Report (Exhibit 99.1).
- Confirm the impact of the acquisition on the company's capital structure and future product pipeline.
- Note the discrepancy between the requested company name (Quantum Biopharma Ltd.) and the actual registrant (FSD Pharma Inc.).